2026 Medicare Part D Changes: What Agents Need Before AEP

For Medicare agents, Part D is becoming one of the most important parts of the client review.

In the past, many drug-plan conversations were built around a few basic questions: What is the monthly premium? Are the prescriptions covered? Is the pharmacy preferred? Those questions still matter, but they are no longer enough.

For 2026, agents need to understand and explain several important Part D rules:

• the 2026 Part D deductible;
• the $2,100 out-of-pocket threshold;
• the continued elimination of the donut hole;
• how catastrophic coverage works;
• the Medicare Prescription Payment Plan;
• the selected-drug subsidy;
• insulin and vaccine cost-sharing rules;
• and what agents should already be watching for 2027 selling.

CMS finalized the 2026 Part D redesign instructions to implement Inflation Reduction Act changes to the defined standard Part D benefit, including selected-drug rules and other Part D redesign provisions. For agents, the practical takeaway is simple:

This article is an agent education guide, not plan-specific advice or a substitute for carrier instructions, CMS guidance, Medicare Plan Finder, state rules, or legal review. Before recommending a plan, verify the client’s current prescriptions, dosage, pharmacy, plan formulary, utilization management, network status, and estimated annual cost.

If you are also preparing for 2027 certification and AEP, keep this guide next to the 2027 Medicare agent certification primer, the Medicare GLP-1 Bridge guide for agents, and your agency’s Scope of Appointment and call-recording workflows.

Quick summary: 2026 Part D numbers agents should know

For 2026, the key Part D figures are:

Medicare.gov says no Medicare drug plan may have a deductible higher than $615 in 2026, and some plans have no deductible. Medicare.gov also explains that, after the deductible stage if the plan has one, enrollees generally pay 25% coinsurance until their out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026. After that, catastrophic coverage begins and the enrollee pays $0 for covered Part D drugs for the rest of the calendar year.

That last phrase matters: covered Part D drugs.

Agents should be careful not to tell clients that “everything is free after $2,100.” The threshold applies to covered Part D drug costs. It is not a cap on premiums, non-covered drugs, dental, vision, medical services, or unrelated health care costs.

1. The 2026 Part D deductible is $615

The 2026 Part D deductible is one of the first numbers agents should be ready to explain.

The maximum deductible for Part D plans in 2026 is $615. Plans can charge less than that, and some plans may have no deductible at all.

That does not mean every client will pay $615 before receiving any benefit. Some plans apply the deductible only to certain drug tiers. Some plans may cover lower-tier generics before the deductible. Some plans may have very different cost-sharing structures depending on pharmacy type, preferred network status, and formulary design.

A good agent explanation sounds like this:

Agents should avoid saying: “Your deductible is $615.” That may be true for some plans and false for others. The better answer is: “The maximum Part D deductible is $615 in 2026, but your actual deductible depends on the plan you choose and the drugs you take.”

That distinction can prevent confusion and complaints later.

2. The 2026 Part D out-of-pocket threshold is $2,100

The biggest consumer-facing number for 2026 is the $2,100 out-of-pocket threshold.

In the 2026 defined standard benefit, initial coverage continues until the beneficiary reaches the $2,100 out-of-pocket threshold for covered Part D drugs. After that, the beneficiary enters catastrophic coverage and pays no cost-sharing for covered Part D drugs for the rest of the year.

This is the answer to the common search question: What is the threshold for Part D in 2026?

The threshold is $2,100.

But agents need to explain it carefully. The $2,100 amount is not the same thing as:

• the deductible;
• the annual premium;
• the maximum cost for all health care;
• the maximum cost for all drugs, including non-covered drugs;
• the Medicare Advantage maximum out-of-pocket limit.

It is the Part D out-of-pocket threshold for covered Part D drugs.

A practical client script:

This is especially important for clients who take expensive brand-name or specialty medications. Those clients may reach the threshold earlier in the year, while clients who take only low-cost generics may never reach it.

3. The donut hole remains eliminated

The old Part D “donut hole” used to create a lot of confusion. For 2026, agents can tell clients that the defined standard benefit no longer includes a separate coverage gap phase.

The 2026 benefit moves from the deductible stage, if the plan has one, to initial coverage, then to catastrophic coverage after the out-of-pocket threshold is reached.

That does not mean every prescription will be cheap all year. Clients can still face high early-year costs because of:

• deductibles;
• coinsurance;
• expensive brand drugs;
• specialty-tier drugs;
• non-preferred pharmacies;
• prior authorization;
• step therapy;
• quantity limits;
• formulary exclusions.

A better client explanation is:

That is more accurate than simply saying: “There is no donut hole anymore, so you do not need to worry.” Clients still need a real drug-cost review.

4. The Medicare Prescription Payment Plan is a cash-flow tool, not a discount

The Medicare Prescription Payment Plan is another area where clients may misunderstand what changed.

CMS explains that the Medicare Prescription Payment Plan gives Part D enrollees the option to pay out-of-pocket prescription drug costs in capped monthly payments instead of all at once at the pharmacy. All Medicare prescription drug plans must offer it.

Medicare.gov is clear that the program may help manage monthly expenses, but it does not save money or lower drug costs.

Agents should explain it this way:

This matters most for clients who have high drug costs early in the year. A client who fills an expensive medication in January may prefer monthly billing instead of paying a large amount at the pharmacy counter.

For 2026 and later years, CMS finalized an automatic election renewal process that extends a Part D enrollee’s participation in the Medicare Prescription Payment Plan for the next calendar year unless the enrollee opts out. That gives agents another review item:

This should become part of the annual Part D review checklist.

5. The selected-drug subsidy matters, but do not turn appointments into technical lectures

One of the more technical 2026 changes is the selected-drug subsidy.

CMS explains that beginning in 2026, the selected-drug subsidy is equal to 10% of the negotiated price of a selected drug. It applies to selected drugs dispensed to applicable beneficiaries below the annual out-of-pocket threshold after the deductible has been met, and it lowers Part D sponsor liability.

That is important for plan economics. It may affect bids, plan liability, formulary strategy, and how plans manage selected drugs.

But for most client appointments, the agent does not need to turn this into a technical lecture. A practical way to explain the client-facing impact is:

Agents should know the selected-drug subsidy exists. But in the appointment, the practical action is still the same: run the drug list, check the formulary, compare estimated annual cost, and document the result.

6. Insulin and vaccine rules still matter

Agents should also keep insulin and adult vaccine rules in the Part D conversation.

CMS’s 2026 Medicare Advantage and Part D final rule fact sheet explains that the Part D deductible does not apply to covered insulin products. Beginning in 2026, the cost-sharing amount for a one-month supply of each covered insulin product is capped at the lesser of $35, 25% of the maximum fair price if applicable, or 25% of the negotiated price under the PDP or MA-PD plan.

CMS also describes no cost-sharing for ACIP-recommended adult vaccines that are covered under Part D.

For agents, this creates two practical review points.

First, do not assume every insulin conversation is identical. Check the exact insulin product, plan formulary, pharmacy, and cost estimate.

Second, for vaccines, make sure the client understands the difference between Part B-covered vaccines and Part D-covered vaccines. The client may not care which part of Medicare pays, but the agent needs to know enough to explain where the cost-sharing protection applies.

For a deeper field explanation, use the companion guide on how the Medicare insulin cap works in 2026, including why insulin may show as 25% even though the covered insulin cost-sharing cap still applies.

A useful client script:

If the client is asking about GLP-1 drugs, do not merge that conversation into the insulin rule. Use the Medicare GLP-1 Bridge guide for agents to separate normal Part D coverage, weight-management use, clinical eligibility, and Bridge-specific cost-sharing.

7. Why agents should already be thinking about 2027

This article targets “2026 Medicare Part D changes” because that is what agents and consumers are searching for now. But many agents searching in 2026 are actually preparing for 2027 plan-year selling.

For 2026, the standard Part D deductible is $615 and the out-of-pocket threshold is $2,100. For 2027, CMS’s rate announcement materials list a $700 deductible and a $2,400 out-of-pocket threshold for the defined standard benefit.

CMS has also finalized rules for 2027 and later years that codify several Inflation Reduction Act Part D redesign provisions, including the elimination of the coverage gap phase, the reduced annual out-of-pocket threshold, no cost-sharing in the catastrophic phase, the Manufacturer Discount Program, and the selected-drug subsidy.

The agent takeaway:

For 2027 plan-year reviews, agents should be ready to update:

• Part D deductible explanations;
• out-of-pocket threshold explanations;
• Medicare Prescription Payment Plan scripts;
• formulary review workflows;
• selected-drug review processes;
• creditable coverage conversations;
• documentation templates.

This is where many agencies fall behind. They may understand the 2026 redesign, but fail to update their 2027 sales process when the plan-year numbers change.

8. Creditable coverage is a watch item for employer and retiree coverage

Most individual Medicare sales agents will not spend every day analyzing employer group drug coverage. But agents should understand why creditable coverage questions are becoming more important.

Medicare.gov explains that a Part D late enrollment penalty can apply when someone goes 63 or more days without Medicare drug coverage or other creditable prescription drug coverage after their Initial Enrollment Period.

Agents should be careful here. Do not casually tell a client: “Your employer plan is probably creditable.”

The better instruction is:

For agents working with employer, union, retiree, or group markets, this is a bigger content opportunity. For agents focused only on individual Medicare sales, it is still worth mentioning because it affects late-enrollment penalty risk.

9. Selected drugs make plan-specific review more important

Medicare drug price negotiation is another reason Part D reviews need to be more detailed.

CMS states that maximum fair prices for the first cycle of 10 selected Part D drugs took effect January 1, 2026. CMS has also published selected-drug materials for initial price applicability year 2027.

Agents should not promise that a selected drug will be cheap in every plan. Negotiation does not remove the need for plan-by-plan analysis.

The practical agent workflow is:

1. Ask whether the client takes any high-cost brand or specialty drugs.
2. Confirm exact drug name, dosage, quantity, and frequency.
3. Check whether the drug is covered.
4. Check tier, prior authorization, step therapy, and quantity limits.
5. Compare preferred retail, standard retail, and mail-order pharmacies.
6. Review estimated annual cost.
7. Explain whether the client is likely to reach the Part D out-of-pocket threshold.
8. Document the plan comparison.

That is the part that matters in the appointment.

10. The practical 2026 Part D review workflow for agents

A good 2026 Part D review should not be rushed.

Agents should build a repeatable workflow that captures the information needed to make a meaningful plan comparison.

Step 1: Get the current medication list

Ask for:

• drug name;
• dosage;
• frequency;
• quantity;
• brand or generic preference;
• prescribing doctor;
• whether the drug changed recently;
• whether the client expects a new medication soon.

Do not rely on last year’s list. Drug lists change. Formularies change. Tiers change. Pharmacies change. Client health changes.

Step 2: Confirm pharmacy preference

Ask:

• preferred retail pharmacy;
• backup pharmacy;
• willingness to use mail order;
• willingness to switch pharmacies for lower cost;
• whether the client uses a specialty pharmacy.

Pharmacy choice can materially change drug cost estimates. A plan that looks good at one pharmacy may look worse at another.

Step 3: Check formulary status

For each medication, review:

• covered or not covered;
• tier;
• deductible treatment;
• prior authorization;
• step therapy;
• quantity limits;
• specialty-tier placement;
• preferred pharmacy pricing;
• mail-order pricing.

This is where many bad recommendations happen. A plan can look attractive on premium but fail the client on one expensive medication.

Step 4: Estimate annual cost, not just monthly premium

Agents should compare:

• monthly premium;
• deductible exposure;
• expected copays or coinsurance;
• whether the client may hit the $2,100 threshold;
• catastrophic-stage impact;
• pharmacy differences;
• Medicare Prescription Payment Plan usefulness.

A low-premium plan is not always the lowest total-cost plan.

Step 5: Explain the $2,100 threshold clearly

Use plain language:

Then clarify: “Your monthly premium does not count toward that amount, and non-covered drugs may not count.”

Step 6: Discuss the Medicare Prescription Payment Plan when relevant

This should be part of the conversation for clients with high early-year drug costs.

Use this explanation:

Step 7: Document the recommendation

A useful documentation note might say:

That kind of note is far better than: “Client chose cheapest Part D plan.”

Part D is too complex for that.

This also connects to broader recordkeeping. If the same client conversation includes a plan-specific appointment, make sure the Scope of Appointment workflow, telephonic enrollment recording workflow, and call recording storage process match the type of interaction.

Common client misunderstandings agents should correct

Which clients should agents prioritize for Part D reviews?

Every Medicare client deserves an annual drug review, but some clients need extra attention.

Prioritize clients who:

• take expensive brand-name drugs;
• take specialty medications;
• use insulin;
• use GLP-1 drugs;
• changed prescriptions in the last year;
• changed pharmacies;
• had a hospital stay or new diagnosis;
• reached catastrophic coverage in a prior year;
• complained about drug costs;
• use mail order;
• receive Extra Help;
• have employer, union, or retiree drug coverage;
• are considering delaying Part D;
• are enrolled in the Medicare Prescription Payment Plan.

These are the clients most likely to be affected by formulary changes, threshold rules, pharmacy pricing, or payment-timing issues.

If you are building a retention campaign around this list, keep the message focused on plan fit rather than generic sales pressure. The TCPA and TPMO lead consent checklist is a useful cross-check before broad outreach.

How agents should explain the 2026 Part D changes in one paragraph

Here is a simple client-facing explanation:

That paragraph answers the main consumer question without oversimplifying the agent’s job.

What agents should do before AEP

Before AEP, agencies should update their Part D sales process.

Update training materials

Include:

• 2026 deductible;
• 2026 out-of-pocket threshold;
• catastrophic-stage explanation;
• Medicare Prescription Payment Plan;
• selected-drug basics;
• insulin and vaccine rules;
• 2027 watch items.

Update client intake forms

Add fields for:

• exact dosage;
• refill frequency;
• preferred pharmacy;
• backup pharmacy;
• mail-order willingness;
• Medicare Prescription Payment Plan participation;
• high-cost drug concerns;
• employer or retiree drug coverage.

Update documentation templates

The agent file should show:

• medications reviewed;
• pharmacy reviewed;
• formulary reviewed;
• utilization management reviewed;
• estimated annual cost reviewed;
• deductible and out-of-pocket threshold explained;
• payment-plan option discussed when relevant;
• client’s reason for selecting the plan.

Update retention campaigns

Create segmented outreach for:

• high drug-cost clients;
• insulin users;
• specialty drug users;
• clients with plan or formulary changes;
• clients using the Medicare Prescription Payment Plan;
• clients who may be affected by 2027 selected-drug pricing;
• clients with employer or retiree drug coverage questions.

AEP is not the time to figure this out manually. Agencies should have the workflow ready before appointments begin.

Frequently asked questions

What are the new Medicare Part D rules for 2026?

The major 2026 Part D items agents should understand are the $615 maximum deductible, the $2,100 out-of-pocket threshold, 25% coinsurance in the defined standard initial coverage phase, no beneficiary cost-sharing in catastrophic coverage for covered Part D drugs, the continued elimination of the coverage gap phase, the Medicare Prescription Payment Plan, the selected-drug subsidy, and special insulin and vaccine cost-sharing rules.

What is the Part D threshold for 2026?

The 2026 Part D out-of-pocket threshold is $2,100. After a beneficiary reaches that threshold for covered Part D drugs, they pay $0 for covered Part D drugs for the rest of the year.

What is the 2026 Part D deductible?

The maximum Part D deductible is $615 in 2026. Some plans may have a lower deductible or no deductible.

Is the donut hole gone in 2026?

Yes. The 2026 defined standard Part D benefit does not include the old separate coverage gap phase. But clients can still have meaningful drug-cost differences because of deductibles, tiers, formularies, pharmacy networks, and utilization management.

Does the $2,100 Part D threshold include premiums?

No. Agents should not describe the threshold as an all-in annual maximum. The threshold is based on out-of-pocket spending for covered Part D drugs, not the client’s monthly plan premium.

Does the Medicare Prescription Payment Plan reduce drug costs?

No. It can spread out-of-pocket drug costs over the year in monthly payments, but it does not reduce the total cost of the drugs.

What should agents watch for 2027?

For 2027, CMS’s Rate Announcement lists a $700 Part D deductible and a $2,400 out-of-pocket threshold for the defined standard benefit. CMS also finalized 2027 and later rules codifying several Part D redesign provisions, including no coverage gap phase and no cost-sharing in catastrophic coverage.

Bottom line for agents

The 2026 Part D changes are not just technical updates. They change how agents should conduct plan reviews.

A strong Part D review now requires more than comparing premiums. Agents need to review prescriptions, dosage, pharmacy, formulary, deductible exposure, estimated annual cost, out-of-pocket threshold impact, Medicare Prescription Payment Plan suitability, and 2027 planning issues.

The agents who do this well will be able to give clients clearer guidance and create better documentation. The agents who do not may end up giving oversimplified answers to increasingly complex drug-plan questions.

Sources

• Final CY 2026 Part D Redesign Program Instructions: Centers for Medicare & Medicaid Services Accessed 2026-06-23.
• How much does Medicare drug coverage cost?: Medicare.gov Accessed 2026-06-23.
• Medicare & You 2026: Medicare.gov Accessed 2026-06-23.
• Medicare Prescription Payment Plan: Centers for Medicare & Medicaid Services Accessed 2026-06-23.
• Contract Year 2026 Medicare Advantage and Part D Final Rule Fact Sheet: Centers for Medicare & Medicaid Services Accessed 2026-06-23.
• 2027 Medicare Advantage and Part D Rate Announcement: Centers for Medicare & Medicaid Services Accessed 2026-06-23.
• Announcement of CY 2027 Medicare Advantage Capitation Rates and Part C and Part D Payment Policies: Centers for Medicare & Medicaid Services Accessed 2026-06-23.
• Selected Drugs and Negotiated Prices: Centers for Medicare & Medicaid Services Accessed 2026-06-23.

Frequently Asked Questions

What are the new Medicare Part D rules for 2026?

The major 2026 Part D items agents should understand are the $615 maximum deductible, the $2,100 out-of-pocket threshold, 25% coinsurance in the defined standard initial coverage phase, no cost-sharing in catastrophic coverage for covered Part D drugs, no separate coverage gap phase, the Medicare Prescription Payment Plan, selected-drug rules, and special insulin and vaccine cost-sharing rules.

What is the Part D threshold for 2026?

The 2026 Part D out-of-pocket threshold is $2,100. After a beneficiary reaches that threshold for covered Part D drugs, they pay $0 for covered Part D drugs for the rest of the year.

What is the 2026 Part D deductible?

The maximum Part D deductible is $615 in 2026. Some plans may have a lower deductible or no deductible, and plans can apply the deductible differently across tiers.

Is the donut hole gone in 2026?

Yes. The redesigned 2026 defined standard Part D benefit does not include the old separate coverage gap phase. Clients can still see meaningful cost differences because deductibles, tiers, formularies, pharmacy networks, prior authorization, step therapy, and coinsurance still matter.

Does the $2,100 Part D threshold include premiums?

No. Agents should not describe the threshold as an all-in annual maximum. The threshold is based on out-of-pocket spending for covered Part D drugs, not the client's monthly plan premium.

Does the Medicare Prescription Payment Plan reduce drug costs?

No. The Medicare Prescription Payment Plan can spread out-of-pocket drug costs over the year in monthly payments, but it does not save money or lower the total cost of the drugs.

What should agents watch for 2027?

For 2027, CMS's Rate Announcement lists a $700 Part D deductible and a $2,400 annual out-of-pocket threshold for the defined standard benefit. Agents should update training, scripts, intake forms, and documentation templates for the 2027 plan year.